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Donors of Allogeneic Hematopoietic Stem Cells
Transplanted into Adult Patients with Acquired
Aplastic Anemia: Multivariate and Propensity
Score-Matched Analysis
Hawk Kim,1 Byung Soo Kim,2 Dong Hwan Kim,3 Myung Soo Hyun,4
Sung Hyun Kim,5 Sung Hwa Bae,6 Jung Hye Choi,7 Sang Kyun Sohn,8
Ho Jin Shin,9 Jong Ho Won,10 Sung-Soo Yoon,11 Deog-Yoen Jo,12
Young Don Joo,13 Jae-Hoo Park,1 Kyoo-Hyung Lee,14 on behalf of The Korean
Society of Blood and Marrow TransplantationWe retrospectively compared the outcomes of 225 patients with adult acquired aplastic anemia (AA) who
underwent allogeneic hematopoietic stem cell transplantation (alloHSCT) from matched related donors
(MRDs), and those treated by alloHSCT from alternative donors (ADs). Univariate and multivariate analyses
of factors associated with survival were performed. Multivariate analysis showed that age at alloHSCTof#31
years, MRD, successful engraftment, absence of acute graft-versus-host disease (aGVHD), and platelet
engraftment at #21 days, were independent predictors of longer survival. In addition, time to aGVHD
and cumulative nonrelapse mortality (NRM) were better in MRD than in AD recipients. Using propensity
score matching (PSM), we performed a case-control study comparing 25 patients in each group who under-
went alloHSCT from MRDs and ADs. Pretransplantation clinical factors were well balanced in either group.
Median survival time was similar, and no statistically significant difference in transplantation outcomes was
apparent when MRD and AD recipients were compared. In conclusion, our results suggest that alloHSCT
from an AD should be considered earlier in adult patients with AA who do not have an MRD.
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The standard and definitive treatment of adults with
severe aplastic anemia (AA) consists of immune suppres-
sion therapy (IST) followed by allogeneic hematopoietic
stem cell transplantation (alloHSCT) from a suitable
matched related donor (MRD) (if available) [1]. Large-
scale studies have shown that the 5-year survival rates of
such patients are over 80% [2-5]. Survival rates are
higher in younger and minimally transfused patients
than in those who are older, or in patients receiving
more extensive transfusion. Patients without an MRD
are given IST as a substitute for alloHSCT fromMRD.
Although the response rates to IST are relatively high,
ranging from 61% to 77%, the relapse rates are also
significant, and range from 12% to 37% [6-9].
AnMRD is available for only 20% to 30%of adults
with AA. The current therapeutic algorithm recom-
mends that, in patients without an MRD, alloHSCT1289
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IST fails, because of the lower survival rate noted
following alloHSCT from an AD. The 5-year survival
rates range from 39% to 61% in such patients [10-12].
However, in recent decades, the outcomes of
alloHSCT-treated patients have improved, suggesting
that alloHSCT from ADs may be rendered more
viable by controlling the complications of alloHSCT
and by adopting high-resolution HLA typing [2,13].
The numbers of alloHSCT treatments from ADs for
AA patients have increased in recent years, and the
2- to 4-year survival rates currently range from 73%
to 89% [14-19], indicating that alloHSCT from ADs
is safe in patients with AA, although the procedure
currently serves as an alternative to alloHSCT from
MRDs.
Although the results of alloHSCT from MRDs in
Korea are similar to those of other countries [3], the
outcomes of IST are poorer in Korea than elsewhere.
In Korea, the response rate to IST was found to be
only 47%, with a 6-year survival rate of 69% [20].
Many transplantation centers hesitate to perform
alloHSCT from ADs because of early and high failure
rates, and because most guidelines do not recommend
alloHSCT from ADs before IST is tried. The recent
success of alloHSCT from ADs suggests that this pro-
cedure may be considered as a first-line therapy, thus
even prior to IST, in Korean patients lacking a suitable
MRD.To determine whether the procedure is safe and
effective, it is necessary to compare the results of
alloHSCT from MRDs and ADs.
Many factors may be prognostic of success in
patients undergoing alloHSCT for severe AA; these
include age, donor/recipient gendermatching, numbers
of cells transfused, useof irradiatedbloodproducts, time
from diagnosis to alloHSCT, stem cell source, dose
of irradiation, HLA matching, method of immune sup-
pression to prevent graft-versus-host disease (GVHD),
prior IST history, and use of antithymocyte antigen
(ATG). However, patients who receive alloHSCT
from ADs usually have an unfavorable prognostic fac-
tor(s) than do those who are recipients of alloHSCT
fromMRDs.
Propensity score matching (PSM) is a statistical
method adjusting prognostic factors that can affect
the choice of 1 among many treatment options, char-
acterized by uneven and differing clinical factors.
Thus, PSM analysis of pretransplantation prognostic
factors may allow selection of an appropriate alterna-
tive treatment method.
In Korea, the frequency of alloHSCT for AA has
increased, and more than 60 patients are treated in
this manner annually [21]. Although several studies
have assessed the features associated with successful al-
loHSCT for AA, most studies have been conducted in
Western countries. Because of differences in ethnicity,
outcomes may vary in Korean patients, suggestinga need for nationwide analysis to assess the outcomes
of alloHSCT for AA. We therefore compared the
outcomes of AA patients receiving alloHSCT from
MRDs and ADs in Korea, and assessed the prognostic
significance of donor type with respect to successful
alloHSCT, by comparing the results of multivariate
and PSM analyses.PATIENTS AND METHODS
Patient Eligibility
Patients were included if severe acquired aplastic
anemia (SAA) was diagnosed, if patients were.15 years
of age at the time of alloHSCT treatment; and if
patients had undergone alloHSCT from an MRD
or AD, regardless of prior IST history. All eligible
patients were fully informed on the nature and purpose
of the present study, and all provided written informed
consent before enrollment. All patients fully understood
that they were entitled to exit the study without any
negative consequences. Exclusion criteria were the
presence of congenital aplasia, including Fanconi
anemia, Diamond-Blackfan syndrome, or congenital
dyskeratosis; or hypoplastic myelodysplastic syndrome.
Data were collected from patients with pure red cell
aplasia (PRCA) and paroxysmal nocturnal hemoglobin-
uria (PNH) during the protocol design phase, but such
patients were not included in final analyses. An MRD
was defined as an HLA fully matched related donor,
and an AD included all other donor types, including
both mismatched related and unrelated donors.
Data Collection
The present study was a retrospective multicenter
work. This protocol was submitted to and approved by
the Korean Society of Blood and Marrow Transplanta-
tion (KSBMT) Clinical Study Committee (approval no.
KSBMT07-02), and the institutional review board
(IRB) of each participating institution also cleared the
work. Case report form (CRF) questionnaires defining
items to be evaluated were provided to institutional in-
vestigators. If CRFs were insufficient or incomplete,
principal investigatorsqueried institutional collaborators
to obtain missing information. Data collection started in
2007 for 6months, and 1 institution added data on 2009.
Evaluation Criteria
The purpose of the studywas to evaluate significant
risk factors predicting survival in patients with AA fol-
lowing alloHSCT. The principal concern of the study,
however, was to define whether alloHSCT from ADs
was comparable in effect to alloHSCT from MRDs.
The hematologic response to IST was assessed during
the first 6 months after treatment. Responses to IST
were required to be sustained upon transfusion, or by
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using a minimum of 2 observations at least 4 weeks
apart. A complete response (CR) was defined as trans-
fusion independence, combined with test data showing
that all cell lines tested were normal with respect to age
and gender (the SAA evaluation). A partial response
(PR) was defined as transfusion independence but the
SAA criteria had not been met. A nonresponse was de-
fined as transfusion dependence or when the peripheral
blood count criteria for PR had not been attained.
Relapse after IST was defined as a decrease in any
peripheral blood cell count to\50%of themedian sus-
tained count observed during the response phase, or as
dependence on transfusion.
ABO incompatibility between donors and recipi-
ents was classified as major (ie, the recipient had
anti-A and/or anti-B antibodies capable of reacting
with antigens on donor red cells), minor (ie, the donor
had anti-A and/or anti-B antibodies capable of react-
ing with antigens on recipient red cells and tissues),
mixed (ie, a transplant involving a group B donor and
a group A recipient, or vice versa), and compatible.
Neutrophil engraftment was noted on the first of 3
consecutive days on which the absolute neutrophil
count (ANC) of a patient was .0.5  109/L after
a nadir, and platelet engraftment was defined as the
first of 7 consecutive days on which the unsupported
platelet count was .20  109/L. Primary graft failure
(or early rejection) was defined as a peripheral ANC
\0.5  109/L, persisting for more than 21 days after
alloHSCT. Secondary graft failure was defined as mar-
row hypoplasia after engraftment, with a requirement
for frequent (more than once weekly) platelet transfu-
sion, or an ANC\0.5  109/L, but without growth
factor requirements extending beyond day 60.
Acute and chronic GVHD (aGVHD, cGVHD)
were diagnosed and graded according to the Seattle cri-
teria [22,23], and sinusoidal obstruction syndrome
(SOS) was diagnosed using McDonald’s guidelines
[24]. Performance status was graded by Eastern
Cooperative Oncology Group (ECOG) performance
scoring. Relapse was defined as reacquisition of trans-
fusion dependence or fulfillment of severe/very severe
criteria after full engraftment.
Definitions of Survival Times
The startpoint for determination of survival param-
eters was the first day of stem cell infusion. Relapse-free
survival (RFS), measured only in patients showing suc-
cessful engraftment and who did not require regular
transfusions, was defined as the time from commence-
ment of a conditioning regimen to the date on which
the patient was first recorded with disease relapse, or
the date of death. Patients without relapse or death
were censored at the date of last follow-up. Time to
relapse was measured from the day of stem cell infusion
to the date on which a patient withdrew from the studybecause of adverse events, progressive disease, insuffi-
cient therapeutic response, death, failure to return for
follow-up, refusal of treatment, refusal to cooperate,
or withdrawal of consent. If none of these events
occurred, patients were censored on the date of last
follow-up. Overall survival (OS) was measured from
the time of commencement of a conditioning regimen
to the date of death, or the last date onwhich the patient
was known to be alive (this constituted censoring).
Statistical Analysis
All analyseswereperformedonan intention-to-treat
basis.The chi-square testwas used to compare categoric
variables and Student’s t-test was employed to compare
continuous variables between any 2 groups. Analysis of
variance (ANOVA) was used to compare variables
among 3 or more groups. Time to engraftment, time
to aGVHD and cGVHD, nonrelapse mortality
(NRM), and relapse, were estimated using the
cumulative incidence function, and differences were
compared employing Gray’s test [25]. Survival curves
were computed according to theKaplan-Meiermethod,
and differences in survival were compared by the log-
rank test. A Cox’s proportional hazard model was used
todetermine the effects on survival of various prognostic
factors, including age, donor/recipient gender match-
ing, number of cells transfused, use of irradiated blood
products, time from diagnosis to alloHSCT, stem cell
source, dose of irradiation, HLA matching, method of
immune suppression employed to prevent GVHD,
prior IST history, and use of ATG. All variables were
dichotomized and converted into categoric classes.
The principal objective of the present studywas to com-
pare differences in OS between recipients of MRD and
AR alloHSCT. To adjust for variations in clinical char-
acteristics among recipients of the 2 types of donor cells,
we calculated a propensity score for each recipient, using
a linear regression model that considered pretransplan-
tation clinical factors. Employing PSM, we performed
a case-control study comparing outcomes of MRD
and AD alloHSCT patients. Variables considered in
multivariate analysis included MRD versus AD, and all
prognostic factors with P values\.1 in univariate analy-
sis. Differences were assessed using a 2-sided test at the
P 5 .05 level of significance. We used the R package
(cmprsk) to analyze cumulative incidence, and SPSS
version 17 for all other statistical analyses.RESULTS
Patients
Our initial patient population included 234
patients with AA who underwent alloHSCT consecu-
tively between 1995 and 2008 at 15 of the 40 transplan-
tation centers in Korea, including most major centers.
After excluding 1 patient with PRCA and 8 with PNH,
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who underwent alloHSCT (Table 1). Of these pa-
tients, 117 (52.0%) were male; and median age at the
time of alloHSCT was 31.2 years (range: 15-63 years).
We determined that 103 (45.8%) patients had received
prior IST, including 66 (29.3%) who were treated with
ATG or ALG; of the latter, only 17 (16.5%) re-
sponded, with CR evident in 2 and PR in 15. ABO
blood-type matching was compatible in 110 (53.7%)
donor-recipient pairs. Stem cell sources included BM
only in 172 (76.4%) patients, PB only in 46 (20.4%),
and both BM and PB in 7 (3.1%); 185 (82.2%) pairs
were fully HLA-matched. Of the 225 donors, 162
(72.0%) were related and 63 (28.0%) unrelated; 152
(67.6%) donors were MRDs and 73 (32.4%) ADs.
Cyclophosphamide-ATG/ALG (Cy-ATG/ALG) was
the most common conditioning regimen, used in 170
(75.6%) patients.Clinical Factors Predicting Survival
The ability of various clinical factors to predict
survival was evaluated (Table 2). We found that none
of patient gender (P 5 .640), female donor-to-maleTable 1. Patient Characteristics
Characteristic n (%)/Median (Range)
Gender
Male 117 (52.0)
Female 108 (48.0)
Median age (years)
At diagnosis 28 (2-62)
At alloHSCT 30.9 (15-63)
Severity of AA
Transfusion-dependent 17 (7.6)
Severe 193 (85.8)
Very severe 15 (6.7)
Prior IST 103 (45.8)
Drug used to treat prior IST
ATG/ALG 66 (29.3)
CsA 69 (30.7)
Oxymetholone 28 (12.4)
Response to prior IST
CR 2 (1.9)
PR 15 (14.6)
No response 86 (83.5)
2nd IST 16 (7.1)
Transfusion prior to alloHSCT
Median PRC units 12 (0-114)
Median PC units 86 (0-812)
Donor
Related 162 (72.0)
Unrelated 63 (28.0)
Matched related 152 (67.6)
Alternative 73 (32.4)
Female-to-male 39 (17.3)
HLA matching
High-resolution typing
Full matching 185 (82.2)
Median no. of mismatches 0 (0-4)
alloHSCT indicates allogeneic hematopoietic stem cell transplantation; AA, apl
PR, partial remission; PRC, packed red cells; PC, platelet concentrate; BM, bon
nuclear cells; Dx, diagnosis; Cy-ATG/ALG, cyclophosphamide-antithymocyte gl
ANC, absolute neutrophil count; SOS, sinusoidal obstruction syndrome; GVHrecipient matching (P 5 .499), ECOG performance
status at alloHSCT (P5 .948), prior PRC transfusion
(P 5 .396), conditioning regimen, BM as a stem cell
source (P 5 .224), development of cGVHD, infused
stem cell dose, or days to neutrophil engraftment
(P 5 .668), significantly predict survival on univariate
analysis, whereas younger age at diagnosis (P 5
.055), compatible ABO typing (P 5 .055), and lower
PC transfusion level prior to alloHSCT (P 5 .063)
were all marginally significant. However, lack of prior
IST (P5 .005), age at alloHSCT#31 years (P5 .001),
time from diagnosis to alloHSCT #6 months (P 5
.008), MRD (P \ .001), HLA full matching (P 5
.019), successful engraftment (P\ .001), absence of si-
nusoidal obstruction syndrome (SOS) (P 5 .035), ab-
sence of GVHD (P 5 .005), and platelet engraftment
at#21 days (P5 .025) were all significantly prognostic
of longer survival.
Multivariate analysis showed that age at alloHSCT
#31 years (P\ .001), MRD (P5 .003), successful en-
graftment (P\ .001), absence of aGVHD (P\ .001),
and platelet engraftment at #21 days (P 5 .026), were
significant independent factors predictive of longer
survival (Table 3). Multivariate analysis also indicatedCharacteristic n (%)/Median (Range)
ABO incompatibility (n 5 205)
Major 43 (21.0)
Minor 38 (17.6)
Mixed 16 (7.8)
Compatible 110 (53.7)
Stem cell infusion
BM only 172 (76.4)
PB only 46 (20.4)
BM and PB 7 (3.1)
Median TNC (107/kg) 33.2 (1.8-217)
Median MNC (107/kg) 9.5 (0.2-414.7)
Median CD34 (106/kg) 3.8 (0.2-30.2)
Median months from Dx to alloHSCT 6.7 (0.2-251.1)
Conditioning regimen
Cy-ATG/ALG 170 (75.6)
TBI-containing 24 (10.7)
Engraftment
Neutrophil 205 (91.1)
PLT 191 (84.9)
Primary graft failure 21 (9.3)
Secondary graft failure 27 (12.0)
Median days to ANC $500/mL 17 (8-32)
Median days to PLT $20,000/mL 21 (5-423)
SOS 19 (8.4)
Mild 10 (4.4)
Moderate 6 (2.7)
Severe 3 (1.3)
GVHD
Acute 51 (22.7)
Grade III/IV 15 (6.6)
Chronic 49 (21.8)
Extensive 19 (8.4)
Relapse 14 (6.2)
astic anemia; IST, immune suppression therapy; CR, complete remission;
e marrow; PB, peripheral blood; TNC, total nuclear cells; MNC, mono-
obulin/antilymphocyte globulin; TBI, total-body irradiation; PLT, platelets;
D, graft-versus-host disease.
Table 2. Factors Predicting Overall Survival
Factor n 5-Year Survival Rate (%) P Value
Female versus male 117 versus 108 74.0 versus 67.7 .640
No prior IST versus prior IST 122 versus 103 77.4 versus 61.9 .005
None versus ATG/ALG for prior IST 160 versus 65 74.7 versus 59.5 .012
None versus CsA for prior IST 156 versus 69 74.9 versus 60.6 .006
Age at alloHSCT #31 years versus >31 years 113 versus 112 81.3 versus 58.1 .001
Time from Dx to alloHSCT #6 months versus >6 months 107 versus 118 78.7 versus 62.8 .008
RD versus URD 162 versus 63 75.6 versus 56.2 .002
MRD versus AD 152 versus 73 76.6 versus 56.8 <.001
ABO compatible versus incompatible 95 versus 110 75.9 versus 59.3 .055
HLA full match versus mismatch 185 versus 40 73.1 versus 55.9 .019
Others versus female donor-to-male recipient 186 versus 39 71.8 versus 63.1 .499
ECOG performance status at alloHSCT; >1 versus #1 33 versus 192 71.8 versus 70.0 .948
Prior PRC transfusion #12 U versus >12 U 160 versus 65 71.9 versus 65.9 .396
Prior PC transfusion #86 U versus >86 U 149 versus 76 75.3 versus 58.7 .063
Conditioning without versus with TBI 24 versus 201 70.9 versus 65.0 .525
Conditioning with versus without ATG/ALG 173 versus 52 71.6 versus 65.5 .628
Cy-ATG/ALG conditioning versus other 170 versus 55 71.6 versus 65.6 .585
BM as a stem cell source versus Others 179 versus 46 72.9 versus 51.6 .224
Successful engraftment versus graft failure 178 versus 47 81.0 versus 32.3 <.001
No SOS versus SOS 206 versus 19 72.0 versus 50.7 .035
No aGVHD versus aGVHD 174 versus 51 75.1 versus 54.4 .005
cGVHD versus No cGVHD 49 versus 176 72.8 versus 70.4 .168
Infused TNC >33 versus #33 (107/kg) 117 versus 108 70.8 versus 69.3 .911
Infused MNC infusion #9.5 versus >9.5 (107/kg) 104 versus 121 72.9 versus 67.7 .647
Infused CD34 infusion >3 versus #3 (106/kg) 144 versus 81 73.3 versus 65.6 .305
Neutrophil engraftment days #17 versus >17 135 versus 90 73.0 versus 66.6 .668
Platelet engraftment days #21 versus >21 88 versus 137 77.4 versus 65.7 .025
5YSR indicates 5-year survival rate; IST, immune suppression therapy; ATG/ALG, antithymocyte globulin/antilymphocyte globulin; CyA, cyclosporine A;
alloHSCT, allogeneic hematopoietic stem cell transplantation; Dx, diagnosis; RD, related donor; URD, unrelated donor; MRD, matched related donor;
AD, alternative donor; PRC, packed red cells; PC, platelet concentrate; TBI, total-body irradiation; Cy, cyclophosphamide; BM, bone marrow; SOS,
sinusoidal obstruction syndrome; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; TNC, total nuclear cells;
MNC, mononuclear cells
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ABO compatibility (P 5 .070), and absence of SOS
(P 5 .069), were marginally significant.
Calculation of Propensity Scores and PSM
Among the pre-alloHSCT variables used to calcu-
late propensity scores were recipient gender; age at
alloHSCT; history of prior IST; ATG/ALG for prior
IST; time from diagnosis to alloHSCT; ABO compati-
bility; HLA matching; female donor-to-male recipient
status; ECOG performance status at alloHSCT;
PRC transfusion; PC transfusion; total-body irridiation
(TBI) conditioning; ATG/ALG conditioning; bone
marrow (BM) as a stem cell source; and numbers of total
nucleated cells (TNC), mononuclear cell (MNC), and
CD341 cells infused.Fromour225patients,we selected
25 propensity score-matched MRD and AD recipients.
Comparison of Pretransplantation
Characteristics in MRD and AD Recipients,
with or without PSM
Thebasic characteristics ofMRDandADrecipients
differed greatly prior to selection. For example, the per-
centages of patients who did not undergo prior IST
(109/152 [71.7%] versus 13/73 [17.8%];P\.001),with-
out HLA full matching (152/152 [100%] versus 33/73
[45.2%]; P \ .001), with a time from diagnosis toalloHSCT of #6 months (87/152 [57.2%] versus 20/
73 [27.4%]; P\ .001), of an age at alloHSCT#31years
(69/152 [45.4%] versus 44/73 [60.3%]; P 5 .046), and
with a history of PRC transfusion of #12 units prior
to alloHSCT (118/152 [77.6%] versus 42/73 [57.5%];
P5 .003), differed significantly inMRD and AD recip-
ients; whereas the percentages of patients who received
TBI conditioning were marginally different (12/152
[7.9%] versus 12/73 [16.4%]; P5 .065). Patient charac-
teristics are shown inTable 4.AfterPSM,however, all of
these pre-alloHSCT characteristics were well matched.Transplantation Outcomes of MRD and AD
Patients Either Unmatched or Matched
In unmatched patients, MRD yielded superior
transplantation outcomes as shown in Table 5. The in-
cidences of granulocyte (5.9% versus 15.1%; P 5
.024), platelet (11.2% versus 23.3%; P 5 .018), and all
(16.4 versus 30.1%; P5 .018) graft failures were signif-
icantly lower, and the median times to neutrophil (17
versus 20 days; P 5 .006) and platelet (21 versus 26
days; P 5 .003) engraftment were significantly shorter
inMRDthan inADrecipients. In addition,MRDrecip-
ients showed significantly lower incidences of aGVHD
(17.8% versus 32.9%; P 5 .011) and treatment-related
mortality (TRM) (19.1% versus 39.7%; P 5 .001), and
a significantly longer OS (P \ .001), than did AD
Table 3. Multivariate Analysis of Survival
Factor HR 95% CI P Value
No prior IST versus prior IST 0.827 0.255-2.685 .752
None versus ATG/ALG for prior IST 0.729 0.334-1.593 .428
None versus CsA for prior IST 0.966 0.420-2.224 .936
Age at alloHSCT #31 years versus >31 years 0.281 0.126-0.423 <.001
Time from Dx to alloHSCT #6 months versus >6 months 0.938 0.482-1.824 .850
MRD versus AD 0.448 0.264-0.759 .003
ABO compatible versus incompatible 0.607 0.354-1.042 .070
HLA full-match versus mismatch 0.261 0.051-1.323 .105
Prior PC transfusion #86 U versus >86 U 0.666 0.365-1.213 .184
Successful engraftment versus graft failure 0.136 0.077-0.238 <.001
No SOS versus SOS 0.494 0.232-1.055 .069
No aGVHD versus aGVHD 0.231 0.126-0.423 <.001
Platelet engraftment days #21 days versus >21 days 0.473 0.245-0.912 .026
CI indicates confidence interval; IST, immune suppression therapy; ATG/ALG, antithymocyte globulin/antilymphocyte globulin; CyA, cyclosporine A;
alloHSCT, allogeneic hematopoietic stem cell transplantation; Dx, diagnosis; MRD, matched related donor; AD, alternative donor; PC, platelet concen-
trate; TBI, total-body irradiation; Cy, cyclophosphamide; BM, bone marrow; SOS, sinusoidal obstruction syndrome; aGVHD, acute graft-versus-host
disease.
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aGVHD (P 5 .01263) and NRM (P 5 .0001583) were
significantly better in the MRD group. In contrast,
MRD patients did not differ in incidence of grade 3/4
aGVHD (5.9% versus 8.2%; P 5 .572); presence of
any cGVHD (21.7% versus 21.9%; P 5 .972); or
development of extensive cGVHD (7.9% versus 9.6%;
P 5 .669), SOS (8.6% versus 8.2%; P 5 .933), or
relapse (7.9% versus 2.7%; P 5 .236); or in times to
relapse (P 5 .2308703) (G3/4 aGVHD [P 5 .516318],
cGVHD [P 5 .814118], and extensive cGVHD [P 5
.581048]), compared to AD patients.
Of our propensity score-matched patients, 8 of 25
MRD and 9 of 25 AD recipients died. The median sur-
vival times of PSM-matched MRD and AD recipients
were 175.4 months and not attained, respectively
(P 5 .514). No relapse was evident in either group
(Figure 1). Times to ANC (P 5 .336) and platelet
(P 5 .705) engraftment, and the incidence of SOSTable 4. Characteristics of Patients with Matched Related and Alt
Character
All Patients, n (%)
MRD (n 5 152) AD (n 5 73)
Male 79 (52.0) 38 (52.1)
No prior IST 109 (71.7) 13 (17.8)
HLA full match 152 (100) 33 (45.2)
Female to male 30 (19.7) 9 (12.3)
ABO-compatible 83 (57.2) 27 (45.0)
ATG/ALG conditioning 115 (75.7) 58 (79.5)
TBI conditioning 12 (7.9) 12 (16.4)
Time from Dx to alloHSCT #6 months 87 (57.2) 20 (27.4)
Age at alloHSCT #31 years 69 (45.4) 44 (60.3)
PB used as stem cells 31 (20.4) 22 (30.1)
Prior PRC transfusion #12 U 118 (77.6) 42 (57.5)
Prior PC transfusion #86 U 106 (69.7) 43 (58.9)
Infused TNC #33 (107/kg) 75 (49.3) 33 (45.2)
Infused MNC #9.5 (107/kg) 70 (46.1) 34 (46.6)
Infused CD34 #3 (106/kg) 54 (35.5) 27 (37.0)
Performance (ECOG) #1 128 (84.2) 64 (87.7)
IST indicates immune suppression therapy; ATG/ALG, antithymocyte globu
alloHSCT, allogeneic hematopoietic stem cell transplantation; PB, peripheral bl
cells; MNC, mononuclear cells.(P 5 .235), did not differ in PSM-matched MRD and
AD recipients (Figure 2), nor were statistically significant
differences in cumulative incidences of aGVHD (P 5
.1550), grade 3/4 aGVHD (P 5 .3275), cGVHD
(P 5 .8002), extensive cGVHD (P 5 .5647), or NRM
(P5 .3655), apparent.DISCUSSION
AlloHSCT is a curative treatment for patients with
severe AA. Many studies have shown that survival is
superior in recipients of MRD than in AD recipients
[2,10]. General guidelines recommend that alloHSCT
be postponed after IST if no suitable MRD is available.
However, it is important to consider the clinical
settings in which alloHSCT is performed. We found
that AD was associated with a greater delay in
alloHSCT after diagnosis, older age at alloHSCT, andernative Donors
Patients Matched by Propensity Score, n (%)
P Value MRD (n 5 25) AD (n 5 25) P Value
1.000 11 (44.0) 11 (44.0) 1.000
<.001 4 (16) 5 (20) .500
<.001 25 (100) 25 (100) —
.192 5 (20.0) 3 (12.0) .351
.125 9 (36.0) 12 (48.0) .284
.614 20 (80.0) 19 (76.0) 1.000
.065 5 (20.0) 3 (12.0) .351
<.001 4 (16.0) 6 (24.0) .725
.046 12 (48.0) 13 (52.0) 1.000
.131 5 (20.0) 6 (24.0) 1.000
.003 18 (72.0) 15 (60.0) .551
.132 18 (72.0) 15 (60.0) .551
.572 10 (40.0) 13 (52.0) .571
1.000 12 (48.0) 12 (48.0) 1.000
.882 12 (48.0) 10 (40.0) .776
.551 22 (88.0) 23 (92.0) .5000
lin/antilymphocyte globulin; TBI, total-body irradiation; Dx, diagnosis;
ood; PRC, packed red cells; PC, platelet concentrate; TNC, total nuclear
Table 5. Transplantation Outcomes in Patients with Matched Related and Alternative Donors
Character
All Patients, n (%) Patients Matched by Propensity Score, n (%)
MRD (n 5 152) AD (n 5 73) P Value MRD (n 5 25) AD (n 5 25) P Value
Graft failure
Granulocytes 9 (5.9) 11 (15.1) .024 3 (12) 2 (8) 1.000
Time to ANC500, days 17 20 .006 19 17 .369
Platelets 17 (11.2) 33 (23.3) .018 5 (20) 4 (16) 1.000
Time to PLT20K, days 21 26 .003 26 24 .914
Any 25 (16.4) 22 (30.1) .018 4 (16) 4 (16) 1.000
Acute GVHD
Any 27 (17.8) 24 (32.9) .011 3 (12) 7 (28) .157
Grade 3/4 9 (5.9) 6 (8.2) .572 0 (0.0) 1 (4.0) 1.000
Chronic GVHD
Any 33 (21.7) 16 (21.9) .972 6 (24.0) 5 (20.0) .733
Extensive 12 (7.9) 7 (9.6) .669 2 (8.0) 1 (4.0) 1.000
SOS 13 (8.6) 6 (8.2) .933 3 (12.0) 0 (0.0) .235
TRM 29 (19.1) 29 (39.7) .001 7 (28.0) 9 (36.0) .544
Relapse 12 (7.9) 2 (2.7) .236 0 (0.0) 0 (0.0) —
OS, median, months NR NR <.001 175.4 NR .514
ANC500 indicates absolute neutrophil count >500/mL; PLT20K, platelet count >20,000/mL; GVHD, graft-versus-host disease; SOS, sinusoidal obstruc-
tion syndrome; TRM, treatment-related mortality; OS, overall survival; NR, not reached.
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unfavorable risk factors for alloHSCT in patients with
AA. Although we utilized multivariate analysis to adjust
for such imbalances, it remain unclear whether such
analysis can completely account for differences in
pretransplantation clinical factors, because selection
bias may have been in play when risk factors for analysis
were chosen. Moreover, our multivariate analysis
included posttransplantation risk factors, some of which
can interact with pretransplantation factors. In addition,
we could not randomize patients to MRD or AD.
PSM is a statistical method used to compare dif-
ferent treatment modalities in clinical settings. PSM
can be employed to eliminate causal inference and
simple selection bias in nonexperimental settings.
The use of PSM allowed us to focus on donor selec-
tion itself.
Among the factors that differed significantly in
univariate analysis between unmatched recipients of
MRD and AD were the absence of prior IST (P 5
.005), age at alloHSCT #31 years (P 5 .001), timeFigure 1. Outcomes of patients undergoing hematopoietic stem cell transplan
and relapse in patients with matched related donors (MRDs); in (B) all patients
was superior in patients with MRDs than in patients with unmatched donors, b
propensity-score-matched (PSM) ADs. Only NRM in unmatched patients diffefrom diagnosis to alloHSCT #6 months (P 5 .008),
MRD (P\ .001), full matching of HLA (P 5 .019),
successful engraftment (P \ .001), no SOS (P 5
.035), no aGVHD (P5 .005), and platelet engraftment
.21 days (P 5 .025), all of which significantly favored
MRD. Several of these factors also featured in pre-
transplantation risk analysis, including no prior IST,
age at alloHSCT #31 years, time from diagnosis to
alloHSCT #6 months, MRD, and full matching of
HLA.
Multivariate analysis showed that age at alloHSCT
#31 years (P\ .001), MRD (P5 .003), successful en-
graftment (P\ .001), and no aGVHD (P\ .001), were
independent factors associated with longer patient sur-
vival, whereas age at diagnosis #28 years (P 5 .090),
ABO compatibility (P 5 .070), and no SOS (P 5
.069), weremarginally significant. These findings indi-
cate that alloHSCT at a younger age from an MRD,
successful engraftment, and the absence of aGVHD,
were predictive of optimal results in patients with
AA. As we could not control donor choice, we aretation. (A) OS, and cumulative incidence of nonrelapse mortality (NRM)
with unmatched donors, and (C) in patients with PSM-matched ADs. OS
ut did not differ significantly between patients with MRDs and those with
red significantly between patients with MRDs and ADs.
Figure 2. Cumulative incidence of transplantation outcomes. Times to granulocyte engraftment (A, B); times to platelet engraftment (C, D); extent of
acute graft-versus-host disease (aGVHD; E, F); and the levels of chronic graft-versus-host disease (cGVHD; G, H), in recipients of all unmatched donors
(A, C, E, G), and propensity score-matched donors (B, D, F, H); are shown.
1296 Biol Blood Marrow Transplant 17:1289-1298, 2011H. Kim et al.unable to accurately predict successful engraftment or
occurrence of aGVHD; it follows that case-control
matching balancing pretransplantation clinical factors
may provide practical insights into donor selection.Although cyclophosphamide-ATG is considered to
be the standard conditioning regimen, the role of ATG
remains questionable when alloHSCT from anMRD is
considered [26]. Irradiation as conditioning is not
Biol Blood Marrow Transplant 17:1289-1298, 2011 1297Comparison between MRD and AD AlloSCT in Adult AA Patientsroutinely performed in patients receiving alloHSCT
from an MRD. In contrast, irradiation has been re-
garded as essential for alloHSCT from an AD; many
recognized conditioning regimens incorporate such ir-
radiation [11,27-29]. However, minimal irradiation
may result in survival outcomes comparable with
those of patients receiving alloHSCT from MRDs
[12,19,30]. In addition, impressive results have been
observed using conditioning regimens lacking
irradiation in AD patients receiving alloHSCT
[16,31]; Korean data support this proposition [14,18].
These findings indicate that non-TBI conditioning reg-
imens may be successful when alloHSCT from ADs is
considered.
Following PSM, pretransplantation clinical factors
were well balanced in our 25MDR and 25 AD patients.
Transplantation outcomes were almost identical in
these 2 groups; 8 and 9 patients, respectively, died,
and similar median survival times (P 5 .514), times to
ANC (P 5 .336) and platelet (P 5 .705) engraftment,
and incidences of sinusoidal obstruction syndrome
(P 5 .235) were observed. Moreover, no differences in
the cumulative incidence of aGVHD (P5 .1550), grade
3/4 aGVHD (P5 .3275), cGVHD (P5 .8002), exten-
sive cGVHD (P 5 .5647), or NRM (P 5 .3655), were
apparent. Thus, in patients with similar pretransplanta-
tion clinical conditions, the outcomes of alloHSCT
were also similar, regardless of donor type.
Hidden bias may be significant when PSM is em-
ployed because matching of observed variables may
result in bias attributable to dormant unobserved con-
founders [32]. The use of PSM tends to select AD
patients with favorable characteristics because all
MRD recipients were HLA fully matched. In addition,
only half of our PSM AD patients were treated with
pretransplantation immunosuppression, another indi-
cator of the relatively favorable characteristics of this
group. In addition, the lack of any difference between
MRD and AD recipients may be attributable to the
small numbers of patients in either group. Although
the incidences of aGVHD (28% versus 12%) and
TRM (36% versus 28%) were greater in the AD group,
the between-group differences were statistically non-
significant and may be attributable to small sample
size. In contrast, the times to neutrophil (19 versus
17 days) and platelet (26 versus 24 days) engraftment
were somewhat greater in the AD group, as was the in-
cidence of SOS (12% versus 0%), although none of
these differences was statistically significant. Our find-
ings may also have been influenced by ethnic homoge-
neity. Thus, all patients and donors were Korean, and
the use of ethnically homogeneous unrelated donors
may have affected our results.
Despite the many limitations of a PSM study, our
results differ from those of previous reports in that
transplantation outcomes were very similar when
MRD and AD groups were compared. AD may be assuccessful as MRD if alloHSCT is performed soon
after diagnosis, in younger patients, and using ABO-
compatible and HLA fully matched donors.ACKNOWLEDGMENTS
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